New breast cancer drug test halted after just 3 patients
NCT ID NCT05128773
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study aimed to see if a new drug called amcenestrant could help prevent breast cancer from coming back in people with hormone receptor-positive early breast cancer who had side effects from standard aromatase inhibitor therapy. It was designed to compare amcenestrant against tamoxifen over 5 years of treatment. However, the trial was stopped early after enrolling only 3 participants, so no conclusions can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
amcenestrant
What this could lead to
If it worked, amcenestrant could offer a better-tolerated alternative to tamoxifen for preventing breast cancer recurrence in patients who cannot take aromatase inhibitors.
What could go wrong
The trial was terminated early with only 3 participants enrolled, so no meaningful results are available. It is unknown if amcenestrant is effective or safe compared to tamoxifen.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number :1521622
Santiago, Reg Metropolitana de Santiago, Chile
-
Investigational Site Number :1561599
Haikou, 570311, China